Embecta Corp. (NASDAQ: EMBC) was unchanged Tuesday, as the global diabetes care company with a 100-year legacy in insulin delivery announced a new landmark publication in the Mayo Clinic Proceedings. The publication introduces the FITTER Forward Expert Recommendations, an updated set of global best practices for insulin injection technique and education. Authored by a panel of 16 diabetes specialists from 13 countries, the FITTER Forward initiative highlights the critical need for improved training and standardization in insulin delivery, aiming to enhance clinical outcomes for millions of people with diabetes worldwide.
According to the study’s authors, Dr. David Klonoff, Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center, Clinical Professor of Medicine at UCSF, “When physicians and nurses discuss insulin treatments, they usually focus on the specific dose, but not so much on how exactly the insulin is administered. However, proper injection technique, proper handling of injection devices, and proper insulin handling can all significantly improve long-term glycemic control.”
“How insulin is injected actually plays a more crucial factor in maintaining target blood glucose levels than many realize. This new recommendation provides healthcare professionals with clear, evidence-based strategies to help ensure that insulin is delivered correctly and safely."
EMBC shares inched up 11 cents to $12.86.
